Recent events in the Middle East focused attention on the renewed threat of chemical warfare. The (6) .
The Chemical Stockpile Disposal Program (CSDP) of the U. S. Army will carry out the intent of Congress regarding the unitary stockpile; details are provided in the CSDP-Final Programmatic Environmental Impact Statement (FPEIS), (7) and summarized by Carnes (8) and Carnes and Watson (9) . Workplans, budgets, and decision criteria for nonstockpile agents and munitions are currently under development (5) .
Two nerve agents [GB (sarin), methylphosphonofluoridate isopropyl ester and VX, S-(diisopropylaminoethyl) methylphosphonothiolate o-ethyl ester], are stockpiled at six continental U. S. military installations. These installations include Anniston Army Depot (ANAD), near Anniston, Alabama; Blue Grass Army Depot (BGAD), near Richmond, Ken- tucky; Newport Army Ammunition Plant (NAAP), near Newport, Indiana; Pine Bluff Arsenal (PBA), near Pine Bluff, Arkansas; Tooele Army Depot (TEAD), near Tooele, Utah; and Umatilla Depot Activity (UMDA), near Umatilla, Oregon (see Table 1 for location of individual agent stockpiles) (7) . A third nerve agent, GA (tabun; N.N-dimethyl phosphoroamidocyanidate ethyl ester), is present in small quantities only at TEAD (7, 10) . Physical and chemical characteristics of these agents are presented in Table 1 Organophosphate (OP) nerve agents were designed specifically to cause incapacitation or death in military use and are particularly effective because of their extremely high acute toxicity. This acute toxicity is three to four orders of magnitude greater than most of the chemically similar OP pesticides, whose acute toxicological endpoints are much the same (15) . The probability of an inadvertent release with off-site consequences during current storage or any disposal alternative considered in the CSDP-FPEIS is extremely low, being estimated to range from 1 in 10-4 to 1 in 10-10 (7, 9) . A credible risk, for purposes of CSDP planning, is conservatively considered to be one with a probability of one in 100 million or greater (2 10-8) (16) . Some of the release scenarios considered in the CSDP-FPEIS include exposure of Army personnel and a few extend to off-site populations. Effects on individuals could range from none to life threatening, depending on factors such as the type and concentration of agent released, the duration of exposure, individual variations in sensitivity, and the availability of antidotes, decontamination, and treatment capability. Some low-probability scenarios could result in catastrophic aggregate effects (i.e., > 1000 fatalities). One alternative considered, and rejected in the FPEIS, was continued storage of the agents for 25 years. This option is estimated to entail a higher number of potential fatalities from credible accidents than on-site disposal (17) .
An analysis of the toxicity of each nerve agent in the stockpile was performed as part of evaluating the on-or off-site destruction options (7) . Watson et al. (18) and Carnes and Watson (9) summarized the results of that analysis. This review is the third in a series of articles in EHP addressing health effects issues related to stockpile destruction. In the first, Munro et al. (10) evaluated nerve and vesicant agent antidotes, decontamination procedures, and treatment protocols for use in a civilian context. In the second, Watson and Griffin (19) detailed the toxicity of vesicant agents, with particular attention to mustard agent carcinogenicity. The present review documents essential information on nerve agent toxicity that is useful to civilian medical personnel and emergency planners involved in preparation for stockpile disposal at each community.
We first review briefly the general features of the nerve agents, signs and symptoms of exposure and mechanism of action, F-M; -biochemical indicators of exposure, and metabolism. We then present indices of acute toxicity of the nerve agents alone and in combination, followed by information on potential delayed and persistent effects of acute exposure. These endpoints include delayed neuropathy, psychological and EEG changes, and cardiac effects. We next review results of studies on chronic or subchronic systemic toxicity, carcinogenicity, genotoxicity, teratogenicity, and reproductive toxicity. Finally, we discuss the implications of the varied acute toxic effects of nerve agent exposure for protection of the general public, as well as emergency and medical personnel.
General Features and Mechanism of Nerve Agent Action
According to Harris and Paxton (20) , GA, or tabun, was the first nerve agent developed for chemical warfare; it was discovered in late 1936 and produced in large scale by 1942 (20, 21) . Subsequent G agents such as GB are both more toxic than GA and also more resistant to hydrolysis. GA contains cyanide instead of fluoride (see Fig. 1 ). It is more volatile than VX (see Table 1 ). Agent GA is stored in relatively small quantities in bulk at only one rather remote continental U. S. site (TEAD) ( Table 1) . Thus, concerns about public health hazards presented by GA in the course of the CSDP are relatively minor compared with those of GB and VX.
Because of its volatility, GA is primarily an inhalation hazard; it tends to disperse rapidly and is not likely to be a contact or ingestion hazard. However, GA is less Figure 1 . Molecular structures of the OP nerve agents GA, GB, and VX [adapted from Dacre (13) and Gordon et al. (14) ].
volatile than GB (Table 1) and would be expected to remain on the skin and in the environment somewhat longer. Although it is not as persistent as VX, under certain weather conditions (light breeze, 20'C or 680F) GA can remain in the environment from 1 to 4 days (22) . Agent GA differs from other G nerve agents in some of its biochemical effects on the brains of exposed animals and also in the rarity of GAinduced convulsions, even at lethal doses (23) .
Agent GB, or sarin, a fluorine-containing OP (Fig. 1) , is the most studied of the three nerve agents considered in this analysis. Because of its high volatility and expected rapid dispersion, GB is the agent of greatest concern for acute inhalation exposures in an unplanned release at those sites housing it (ANAD, BGAD, PBA, TEAD, and UMDA; Table 1 ). Because of its high volatility, GB is not a great concern from the standpoint of reentry to a previously contaminated area. GB is somewhat less effective as a skin penetrant than as an inhalant because it evaporates so rapidly from the skin.
Agent VX, a sulfur-containing OP ( Fig. 1) , is, by any route of exposure, the most potent of all the nerve agents discussed here (Table 2) . When compared to the G agents, VX is more stable, more resistant to detoxification, less volatile, more efficient at skin penetration, and Table 1 . Chemical and physical properties, location, and type of chemical munitions (11, 12) 75 (150C) (miscible d9.40C) ff a~--ME I-m ore environmentally persistent. Because of these characteristics, VX is more effective as a skin penetrant and lethal contact agent rather than as an inhalation threat.
Signs and Symptoms of Exposure
The nerve agents are among the most potent of all chemical warfare agents and are highly toxic in both liquid and vapor form. In vapor or aerosol form, nerve agents can be inhaled or absorbed through the skin or the conjunctiva of the eye; as a liquid, they can be absorbed through the skin, conjunctiva, and upper gastrointestinal tract (38) . Because they are essentially colorless, odorless, tasteless, and nonirritating to the skin, their entry into the body may not be perceived by the individual until grave signs and symptoms appear.
Within seconds after exposure to low levels of nerve agent vapor, local effects may be observed in the eyes and the respiratory system of humans. Depending on the agent and the dosage, the local ocular effects may be a constriction of the pupils of the eye (miosis) lasting only several days or a prolonged miosis persisting for many weeks (39, 40) , pain, and/or dim vision (29) . Respiratory effects may include bronchoconstriction, excess secretion in airways, wheezing, and labored breathing (25p. The time of onset of moderate systemic effects depends in part on the route of exposure; it is within seconds to a minute or two after inhalation, within 45 [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] (11, 21) 200-400 (11, 22) 187 (11) 320 (11) 960 (11) 450 (11) -20,000-40,000 (11, 22) 14-21 (27) (11) 0.084 (11) 0.063 (11) 0.07 (11) 0.311 (34) 1.06 (11) 100. (22) 300 (26) 0.9(11) 70(11) 100 (11, 22, 25) 74 (11) 60 (11) 120 (11) 180 (11) 220(11) 240,310 (11) 15,000 (11) 12,000 (11) 2,000 (11) 24 (11) 115.9(11) 10.8(11) 6.2(11) 4.4(11) 2.5(11) 1-9.2 (11, 31) 0.014(11) 0.020 (11) 0.015(11) 0.010 (11) 0.015-0.018 (11, 32) 0.0147 (33) 0.045 (11) 0.07-0.113 (34) (35) (36) 30 (11) 36 (22) -50 (11) 15a (11) 17a (11) 40 (11) 60, 3,600e (11) 6,360e (11) 4.6, 89g ( 11) 8.3, 28 ( 11) 539 ' (26) (11, 28) 0.0079 (11) 0.0141 (11) 0.10 (11) 35-72 (11, 22, 27) 75 (27) 8,000 (11) 2-4 (25) 28 (25) 0.5 (25) 4.0 (25) 24 (11) 0.09 (37) 1.6 (36) 0.0314 (11) 0.02 (37) 8Only head exposed. bWind speed 0.01 mph. CWind speed 15 20-50 (24) 25ab (11) 8, 308c ( fl) 7 (11) 75, 300' (24) 3.5,31.8 (11) 124,180 (11) 5-15 (24) 30-150 (24) min after ingestion, and within 2-18 hr after application on the skin (38, 41) . Exposure to lethal doses, however, can lead to collapse within seconds and death within 10 min after a single deep inhalation (21) . After short-term (acute) exposure, mild systemic effects may last for several hours to days, whereas moderately severe symptoms can last for 1-6 days. During the recovery period, symptoms may recur intermittently, particularly after physical exertion (38) .
The toxic actions of nerve agents are due primarily to their ability to inhibit acetylcholinesterase (AChE), an enzyme responsible for the breakdown of the neurotransmitter acetylcholine (ACh (38) . Finally, ACh accumulation affects the nerves controlling skeletal muscle, resulting in a dosedependent generalized weakness that increases with exertion, as well as muscle twitching and fasciculation, cramping, and even flaccid paralysis.
Respiratory failure, the immediate cause of death in nerve agent exposure, is an example of an effect that occurs as the result of ACh accumulation at several sites in the nervous system. Depression of the brain's respiratory center, neuromuscular block of the respiratory muscles, bronchial constriction, and increased lung secretions are all factors contributing to nerve agentinduced respiratory failure; the relative importance of each depends on the species studied, the nerve agent, and the dosage used (42) (43) (44) (45) (46) (47) (48) .
Recent interest has developed in the acute behavioral toxicity of nerve agents. In this relatively new field of investigation, animals are tested for changes in motor and learning behavior after exposure to the compound of interest. Karczmar (49) has listed the CNS effects, including behavioral and mental health effects, that have been observed with several anticholinesterase chemicals. To date, the number of these effects that can be ascribed to nerve agent exposure is limited. In most cases, motor effects in animals appeared at levels of exposure that caused mild (some salivation, fine tremors) to moderate (excessive salivation and weeping, generalized tremors) toxic effects (36, (50) (51) (52) (53) (54) . However, some animal tests indicate acute effects on learning behavior at exposure levels below those that cause signs of nerve agent poisoning (51, 53) . Results of such studies must be interpreted with much caution (55) . Applicability to humans is suggested by preliminary work in volunteers exposed to VX, demonstrating that performance on a number facility test was impaired to a statistically significant extent (p < 0.01) in conjunction with minimal or absent physical signs and symptoms (56) .
Mild to severe human exposures to nerve agents have been associated with other mental and emotional effects. These range from giddiness and loss of ability to concentrate through anxiety, tension, and irritability, to withdrawal, depression, insomnia, and nightmares (56,5X. Such effects and associated EEG changes were experienced in concert with the onset of nausea and other symptoms in the case of GB, or earlier in the case of VX. Some mental and emotional effects may persist for hours, days, or weeks, depending partly on the severity of exposure.
Agent-induced ACh accumulation generates side effects that involve action on other CNS neurotransmitter systems (e.g., norepinephrine, dopamine, y-aminobutyric acid). Numerous biological effects result (58) (59) (60) (61) including hypothermia in rats (61, 62) , prolonged analgesia in mice (63) , and brain and cardiac lesions in animals surviving high doses of nerve agents (64, 65) .
The interplay of the various neurotransmitters within the nervous system probably results in these varied side effects (45, 66) , although nerve agents may exert direct effects on these same noncholinergic systems (67) (68) (69) Two types of ChE activity can be measured in blood, red blood cell AChE (RBC-ChE), and nonspecific plasma ChE (butyryl ChE or pseudocholinesterese). Systemic effects are seen in about 50% of exposed volunteers when RBC-ChE is 20-25% of normal baseline (a depression of 75-80%) (56, 57, (70) (71) (72) (57, 72, 74) . Agent GB also preferentially inhibits RBC-ChE (75) , although not to the same extent as VX. Furthermore, plasma ChE is more labile than RBC-ChE, being affected by gender, age, and oral contraceptive use (76) , as well as genetic determinants, disease states, nutritional status, hormonal changes, race, and circadian patterns (77, 78) . Plasma and RBC-ChE do serve a protective function, complexing with nerve agent and thus reducing the concentration of free nerve agent available to complex with tissue AChE (Fig. 2) .
Because of the variability of blood ChE activity (both plasma and RBC) in unexposed individuals, it is difficult to determine conclusively from a single test whether a person has had a recent exposure to a cholinesterase inhibitor, especially if the exposure is minor (79, 80 
Metabolism
The detoxification or breakdown of GA within the body proceeds at a low rate (2X), by way of the enzyme diisopropylfluorophosphatase (formerly termed tabunase), which has been identified in sever- Table 2 for LD50 values Table 2 are merely estimates (11, 22) . This is evident in a compar- (28) . GB has been thought by some to act primarily on the peripheral nervous system; however, respiratory arrest induced in cats by an IV dose equivalent to one-half the feline LD50 (48) was mediated through effects on the central nervous system. GB is very efficient at producing central respiratory arrest in guinea pigs and cats at IV doses too low to cause an effect on the respiratory muscles (32 (89) .
Once GB is in the blood, it can penetrate the blood-brain barrier. Cholinesterase inhibitors vary in their ability to pass through this barrier, a property that has been related to the lipid solubility of the compound (90) . Within the brains of mice injected intramuscularly with GB, Bajgar (91, 92) observed regional differences in AChE inhibition. He concluded that the differences in AChE inhibition were due to regional differences in GB penetration rather than to a differential selectivity of GB for AChE in specific parts of the brain. Studies of isolated, blood-perfused in situ dog brains administered GB via intracarotid arterial injection (93) and of the brains of dogs after IV injection of GB (88) also showed regional differences in AChE activity. Studies in rats demonstrated that more than 94% of apparent GB bound to AChE in the brains 30 min (56) after injection is actually the GB metabolite isopropyl methylphosphonic acid (94) . Mechanisms other than (or in addition to) AChE inhibition appear to be responsible for the observed toxicity of GB to the brain. In rats, Harris et al. (95) reported that 51% of the GB found in the brain was bound to sites other than AChE. In studies of spontaneous recovery from central respiratory failure in guinea pigs, respiratory recovery did not correlate with recovery of brainstem AChE levels (44) . Adams and his colleagues concluded that the recovery occurred through a desensitization of the ACh receptors to the excess ACh, but it is also possible that AChE inhibition was not actually responsible for the initial respiratory failure. GB causes a number of noncholinergic effects in the brain, including effects on other neurotransmitters and enzymes. Most effects are too detailed to discuss individually in this analysis, but all emphasize the point that GB does much more than simply inhibit AChE in the brain (23,58,59,61,67,96,97. Data on human responses to GB come from accidental exposures and from limited studies on low doses of GB given to volunteers. In one incident of accidental exposure to GB vapors (estimated at 0.09 mg/mi3 for an undefined duration), two men had significantly lowered RBC-ChE for [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] days (one showed depression to 19% of baseline activity, the other to 84% of baseline) and extreme miosis that persisted for 30-45 days, but no other signs or symptoms of nerve agent poisoning (39) . Other accidental inhalation exposures to GB with similar recovery times for RBCChE activity and miosis were described by Sidell (40) . In one, the individual manifested severe symptoms and required respiratory assistance and extended hospitalization after cleaning a GB-contaminated area while wearing defective protective gear. In the other case, three workers who were in an area with a leaky GB storage container suffered temporary symptoms, such as transient mild respiratory distress, together with marked miosis and RBC-ChE activity depression. The RBC-ChE depression required 3 months for full recovery; the miosis (measured in the dark) recovered in 30-60 days. Grob and Harvey (57) reported the effects in humans of administered low doses of GB. When either 0.003 or 0.005 mg/kg of GB was injected directly into an artery in the arm of one volunteer, Grob and Harvey observed some initial local effects (reduction in grip strength, tremors after exercise) followed by systemic effects, including many of the symptoms listed earlier. These doses, which correspond to 21% and 36% of the estimated human IV LD50, resulted in RBC-ChE activity reductions to 52% and 28% of original activity (i.e., depressions of 48% and 72%) and plasma ChE activity reductions to 61% and 42% (i.e., depressions of 39% and 58%), respectively.
After combining with a ChE molecule, the agent-ChE complex may either spontaneously dissociate (resulting in reactivation of the ChE) or "age," in which case the agent-ChE complex becomes resistant to reactivation by an oxime antidote. Aging is thought to result from stabilization of the nerve agent-ChE complex by loss of an alkyl or alkoxy group (Fig. 3) . In agreement with Grob and Harvey's work (57), Sidell and Groff (56) observed little, if any, spontaneous reactivation of RBC-ChE after GB administration to volunteers. Furthermore, the GB-ChE complex aged at a moderate pace, with aging 50-60% complete 5 hr after GB infusion (56) .
When GB was given orally to 10 volunteers, approximately 3.5 times as much GB (in mg/kg) was needed to produce the same degree of plasma or RBC-ChE activity depression as previously observed with intra-arterial injection (see Table 4 ) (57) . With the oral administration, Grob and Harvey noted a narrow margin between doses that produce mild signs and symptoms and those that produce moderately severe effects. They also noted that, after the disappearance of signs and symptoms, an increased susceptibility (in terms of type and severity of responses) remains to further GB exposure within 24 hr of the first exposure. Anorexia, nausea, and chest tightness were among the first symptoms Volume 102, Number 1, January 1994 I WU 9- Figure 3 . The nerve agent-acetylcholinesterase (AChE) complex may undergo either spontaneous reactivation by hydrolysis or stabilization ("aging") by loss of an alkyl or alkoxy group; stabilization proceeds at a faster rate than hydrolysis and therefore predominates. In humans, the GB-AChE complex is 50-60% aged by 5 hr, whereas VX ages more slowly, with only 40% aged at 48 hr after exposure (56).
reported; abdominal cramping, vomiting, and diarrhea were among later effects; miosis was not observed after oral administration. The possibility of oral exposure of the population to GB is remote because GB dissipates rapidly under most environmental conditions. Only when temperatures are 00 or less can GB persist for a few hours as a ground contaminant (22, 98) .
As mentioned previously, GB vapor is less effective as a toxic skin penetrant than as an inhalant. The estimated human LCt5O (clothed, resting) for dermal toxicity is 150 times higher than the estimated human LCt50 for inhalation (Table 2) . Fielding (28) summarizes information from several sources, some still classified. Rapid evaporation from the skin is the primary factor in the relatively low dermal toxicity of GB; if evaporation is prevented (i.e., by covering the exposed skin with a cup), the toxicity of GB increases almost 100-fold (99) . Another factor limiting the dermal toxicity is the reaction of GB with skin constituents, which attenuates the amount of GB that reaches target tissues (100). Fats such as lanolin and lard have been shown to enhance the skin penetration of GB, probably by dissolving the agent and by preventing evaporation (28) . Mechanical abrasion of rabbit skin increased GB dermal toxicity 100-fold (101). Fielding (28) relates a tragic incident that illustrates the wide individual variability in dermal sensitivity to GB. Seventeen of 18 men exposed dermally to 200 mg of GB (12% of the estimated dermal LD50 for a 70 kg man) through two layers of clothing showed no signs or symptoms of GB poisoning; the eighteenth man died shortly after the onset of exposure, despite immediate treatment when signs of nerve agent poisoning appeared.
In a review of GB toxicity, McNamara and Leitnaker (25) state: "Absorption through the conjunctiva causes local effects but negligible systemic effects." Grob and Harvey (57) instilled 0.0003 mg GB in the eyes (conjunctival sacs) of volunteers and noted a marked miosis that began at 10 min and slowly diminished over a period of 60 hr. At a dose of 0.0009 mg, the pupillary constriction that occurred was near maximal for 72 hr and did not disappear until after 90 hr. In this study, miosis was measured in the light; other studies in which it was measured in the dark showed it persisted for weeks. No depression of blood ChE activity was noted at either dose level. In studies on GB applied to the conjunctival sac of guinea pigs, a rapid dose-dependent depression ofAChE activity in the iris and cornea was noted with a lesser inhibition of AChE in the retina (retina required 10 times the iris dose to achieve the same AChE inhibition), but no examination was made of RBC-ChE depression or other systemic effects in the treated guinea pigs (102) . However, ocular LD50 values are available for several animal species that are equivalent to the LD50 values for subcutaneous injection (11) . This suggests that systemic effects are possible with GB absorption through the conjunctiva and possibly the cornea of the eye.
Studies of the retention and absorption of GB vapors by resting or exercising men demonstrated that the inactive men retained a higher percentage of the inhaled GB (82) . Under similar exposure conditions of time and concentration, however, the active men received a larger dose of GB because of their greater air intake.
In determining the lowest concentration of GB that produces a biological effect, miosis provides a sensitive indicator for nerve agent exposure in humans. Questions, however, cloud the validity of the estimated no effects (0.5 mg-min/m3) concentration-time product (Ct) for miosis by GB ( Table 2 ). The basis for this determination by McNamara (25) derived their no-effects value of 0.5 mg-min/m3 from Johns's data. We consider the true no-effects level likely to lie below 0.5 mg-min/m3. The lack of raw data and absence of measures of variability in Johns's (103) report hinder precise reanalysis. Estimates of a human noeffects level for VX, as discussed below, were based in part on these for GB; the VX estimate consequently suffers from a similar question of reliability. Agent VX A contributing factor to the high toxicity of VX may be its preferential reaction with AChE. Unlike the G agents, VX depresses RBC-ChE activity significantly more than plasma ChE in humans (56) ; the result is that more VX is available to react specifically with the target enzyme, AChE. Less VX is required than GB to reduce RBCChE 50% below baseline levels in humans by all routes of administration for which data are available (see Table 4 ).
Once inside the body, VX not only inhibits AChE activity but also reacts directly with the ACh receptors and other neurotransmitter receptors (68, 97, 104 Two other features of VX toxicity are worthy of mention. First, in contrast to observations on GB, the VX-RBC-ChE complex has been found to undergo a significant degree of spontaneous reactivation in humans. In a study by Sidell and Groff (56) , spontaneous reactivation of human RBC-ChE proceeded at a rate of about 1%/hr over the first 70 hr after IV administration of VX.
A second feature of VX toxicity is the lack of aging or stabilization of the agentChE complex and the relative ease of reactivation of VX-poisoned enzyme by oxime antidotes in humans (56) . By 48 hr after exposure, no aging was observed. The VXChE complex was more easily reactivated by oxime antidote at all times up to 48 hr after exposure (when the experiment was terminated) than was GB-ChE.
Estimates are available for human lethal inhalation doses of VX in both aerosol (small particles) and vapor (gas) phases (Table 2) . Animal inhalation data are available primarily for VX aerosol. In most cases, only the animals' heads and _=== not their total bodies were exposed, so as to limit the skin absorption of VX. The mouse LCt50 values for both vapor and aerosol were obtained with total-body exposure; in the case of VX aerosol, skin absorption appears to contribute to the total toxicity. The estimated human LCt5O values are equivalent for vapor and aerosol. However, it would probably be difficult to achieve a high vapor concentration of VX because of its low volatility; therefore, it is likely that a longer exposure to VX vapor would be necessary to achieve the same endpoint.
It should be borne in mind that the VX LD50 values for humans have been derived from mathematical models, extrapolations from animal data, and estimates from sublethal experimentation in humans. Many of the original reports in which these human values were derived are confidential and unavailable for open-literature review. In general, AChE activity levels have been used as indicators of VX toxicity in humans. However, extrapolation to LD50
estimates from AChE activity determinations may have little meaning because of the poor correlation between AChE activity and toxicity in animals and wide variations in RBC-ChE levels at which toxic effects occurred in human studies (56, 74) .
Dermal absorption is a more likely route of VX exposure than inhalation; moreover, dermal toxicity is more likely to occur from the absorption of VX aerosol or liquid than from the vapor. The LCt estimates for dermal absorption are established by exposure of animals to VX vapor or aerosol in a special chamber in which only the body is exposed. The animals were often shaved, clipped, or depilated before exposure to approximate human skin exposure, and the wind speed within the chamber was varied to simulate a range of meteorological conditions.
Although wind speeds of 20 mph may never be encountered in an unplanned release of VX, it is important to realize that wind speed can significantly increase the dermal toxicity of VX (Table 2) .
Although the animal data summarized in Table 2 primarily show the influence of wind speed, other factors affecting the dermal LCt50 values include particle size and degree of skin exposure (clothed or bare).
Krackow (24) calculated dermal LCt5O values for men wearing gas masks so that only the neck, ears, hands, and wrists were exposed to aerosol particles ranging in size from 5 to 15 pm at wind velocities from 0 to 10 mph. Under these conditions, a lower LCt5O (75 mg-min/m3) was estimated for the larger particles with the higher wind velocity, while an LCt5O of 300 mgmin/m3 was for the smaller particles at the lowest wind speed. Other data of Krackow suggest that, with 10-pm particles and 20-mph winds (or 20-pm particles and 10-mph winds), the LCt5O might be as low as Table 2 for VX vapor are based on VX vapor containing 2-pm particles (11).
These exposure conditions represent a hybrid vapor/aerosol situation. Fielding (28) considers that the dermal LCt5O values for VX vapor and VX aerosol would be similar under conditions of high concentrations in air and short exposure times. With lower vapor concentrations, Fielding (28) notes that "doubt has been expressed regarding the dermal lethality of VX vapor to humans in view of the possibility that the (systemic metabolism and) excretion rate may be greater than the skin-absorption rate."
The amount of skin surface exposed to VX vapor or aerosol is of obvious importance. Clothing is estimated to reduce by 10-fold the dermal vapor toxicity of VX (see Table 2 ). Not all body areas, however, are equally permeable to VX. The doses of VX necessary to cause 70% inhibition of AChE when applied to equal areas of the human cheek, forehead, abdomen, and volar surface (i.e., palm side) of the forearm have been estimated to be 0.0051, 0.0112, 0.0318, and 0.04 mg/kg, respectively (107, 108) . The differences in absorption are important in evaluating studies in which the forearm is exposed and extrapolations are made to total-body exposure. Craig et al. (108) measured the dermal absorption of liquid VX through the cheeks and the forearms men at environmental temperatures ranging from -18°t o 460C. The fraction of the applied dose that penetrated in 3 hr ranged from 3.5% at -18°C to 31.9% at 46°C for the cheek and from 0.4% at +18°C to 2.9% at 46°C for the forearm. Wide individual differences in RBC-ChE depression were seen for both skin sites and most doses tested; in some cases, responses ranged from 0 to 100% depression (108) . The wide range of individual responses to dermal VX exposure, caused in part by differences in penetrability of the skin in various parts of the body, makes the prediction of a human dermal VX LD50 value difficult. Thus, ranges are given rather than single values.
Because skin can act as a storage depot for VX with movement from this depot promoted by increased temperature, the authors suggest that cooling of the skin surface after dermal exposure to VX can delay absorption until treatment is possible. Also note that immediate decontamination should be a particularly effective procedure for dermal VX exposure because of the slowness of its skin penetration. However, if decontamination is delayed until 3 hr after exposure, significant lowering of RBC-ChE continues after decontamination (108) . Specific decontamination procedures following nerve agent exposure can be found in Munro et al. (10) .
The estimated IV LD50 for humans (0.008 mg/kg) is similar to that determined for many animal species, with the major exception of the mouse, which is less sensitive. Low doses of VX (0.001 mg/kg, IV) were administered to volunteers to assess correlation of dose with the degree of AChE inhibition or the presence of clinical signs and symptoms. By injecting VX directly into the bloodstream, the wide differences in individual skin absorption observed in other studies (108) can be bypassed. In four men who received 0.001 mg/kg VX in a 4-hr infusion, good agreement was observed between the individual percent decrease (50%) in RBC-ChE activity compared with preinfusion AChE levels (74). (It is not possible to compare the range of the absolute AChE values because these were not given.) In another study, reported by Sidell and Groff (56) , a group of 34 men were given doses ranging from 0.0012 to 0.0017 mg/kg in an attempt to find an IV dose of VX that would cause 75% inhibition of RBC-ChE levels. In this dose range, most subjects had transient symptoms of lightheadedness and some experienced nausea and vomiting, with the most prominent effects occurring 1 hr after injection, when the RBC-ChE inhibition was maximal. No miosis was observed, even with 90% inhibition of RBC-ChE activity. A dose of 0.0015 mg/kg produced 75% inhibition of the baseline AChE levels; linear regression analysis of the doseresponse curve gave 0.0011 mg/kg as the estimated dose causing 50% decrease in RBC-ChE activity (see Table 4 ).
There Table 4 ). At oral doses ranging from 0.002 to 0.0045 mg/kg, only a few subjects (5/32) suffered any gastrointestinal signs or symptoms, and there were no changes in heart rate, blood pressure, or pupil size in any of the subjects. Eating 30 min before drinking the VX solution appeared to enhance the RBC-ChE inhibition; tap water (as compared with a 5% dextrose solution) seemed to retard the anti-RBC-ChE activity. In an earlier study, volunteers were given four oral doses/day of VX in drinking water for 7 days (concentration about 0.05 mg/l in four 500-ml portions; individual daily dose of 0.00143 mg/kg) (112) . No signs or symptoms of toxicity were observed although RBC-ChE was 40% ofbaseline by day 7.
Estimates have also been made for human ICt50 either by inhalation or by skin absorption of VX aerosol or vapor ( Table  2 ). The ranges in these estimates are due in part to different test conditions (i.e., varied particle sizes in the case of aerosols and different wind velocities). Fielding (28) notes that these ranges may also depend on what is meant by incapacitation.
Estimates have been made for the lowest air concentration of VX that produces miosis, one of the more sensitive indices of human exposure to the vapors of anticholinesterase compounds. The estimated ECt50 found in Table 2 for pupillary constriction by VX is an extrapolation from the derived value for GB in humans (25) . To obtain the VX ECt50 for humans, the estimated ECt5O for miosis in humans exposed to GB was first compared with the minimum dose of GB that causes miosis in rabbits, and the assumption was made that man is twice as sensitive as the rabbit. This factor of two was then applied to the concentration of VX that produces pupillary constriction in rabbits to arrive at the minimum concentration of VX that would be expected to cause miosis in humans (7) .
Similarly, the VX no-effects doses for miosis and for tremors are based on extrapolations from derived values for GB. Because these VX estimates are used to determine presumed safe levels for human exposure to VX, more research is needed to determine whether these minimum and noeffects values are credible.
The effects of acute VX exposure on mood and mental function are similar to those of GB. Kimura et al. (74) Comparative Toxicity of GA, GB, and VX The relative potency of GA, GB, and VX varies with the route of exposure. Inhalation or percutaneous absorption of vapor or aerosol demonstrates that VX is more toxic than GB, which is more toxic than GA (i.e., VX > GB > GA). The dermal toxicity ranking is VX > GA > GB, while the ranking based on estimates of IV toxicity is VX > GA = GB. These differences relate to varying physical, chemical, and toxicological properties among the nerve agents. Agent VX, for example, is not only much less volatile than the G
The human inhalation toxicity of GA vapor is approximately half that of GB (Table 2) ; this difference is well supported by the animal data. GA appears to be more toxic to the ciliary muscles of the eyes than GB because constriction of pupils occurs at a lower concentration of GA [i.e., minimum effective doses of 0.9 and 2-4 mgmin/m3, respectively (11) ]. The estimated LD50 for GA toxicity in humans by skin absorption is roughly equivalent to the estimate for GB, and the human IV LD50 estimate for GA is equal to that for GB. The equivalencies of these estimates are not necessarily supported by the animal data, but no discussions of the bases for the human estimates are given in the source documents (11, 21) .
Although GB is less toxic than VX by a variety of exposure routes, GB may actually be more toxic than VX at the neuromuscular junction. When GB or any one of several V agents related to VX was applied directly to the isolated rat diaphragm at the neuromuscular junction (thereby eliminating factors such as absorption efficiencies and attenuation differences), GB was found to be twice as potent as the V agents (113) . Intravenous infusion of GA, GB, or VX in cats at the rate of one LD50 per 15 min demonstrated that 0.5 LD50 of GB was sufficient to induce respiratory arrest, whereas 1.25 and 15 LD50 doses were needed for GA and VX, respectively (48). These differences reflect the rapidity of the toxic action of GB compared with VX and the somewhat higher toxicity compared with GA.
In comparison with GB human exposure estimates, VX is estimated to be approximately twice as toxic by inhalation, 10 times as toxic by oral administration, and approximately 170 times as toxic after skin exposure (114) . Under conditions favorable for skin penetration, VX can be about 1000 times as toxic as GB in rabbits (28) . The evaporation of VX from the skin is almost negligible, whereas GB evaporates in a matter of minutes (see Table 1 for comparative volatility data). Agent GB penetrates the skin more rapidly than VX, but VX undergoes virtually no degradation as it slowly penetrates the skin; thus, more of this compound is able to reach the bloodstream (115) . Whereas GB skin penetration in rabbits appeared to be complete by 30 min (100) [with a penetration efficiency of nonevaporating GB calculated to be only 0.04% (28)], complete penetration by VX, with essentially 100% of the skin dose reaching the circulatory system, required about 4.5 hr (116) . In vitro stud-
ies suggest that VX can penetrate in unaltered form through the epidermis and dermis of the skin, penetrate through the nerve membranes, and can accumulate within the nerve cells (117) .
A number of investigators have reported the distinctly slower toxic action of VX as compared with the G agents, as well as a slower rate of recovery (105, 118) . This delay cannot be attributed only to slower skin penetration because a slower response is also observed when VX is administered intravenously (48, 56) . With GB there is essentially no difference between the 15-min and 24-hr lethal IV dose; with VX there is an approximate twofold difference (28) . It is important, therefore, in determining LD50 and LCt5O levels for VX to allow enough time to accurately assess the toxicity. Although the biological basis for this delay is not fully understood, Fielding (28) hypothesized that the larger molecular size (see Fig. 1 ) and different solubility characteristics of VX may cause it to diffuse more slowly than G agents through tissues and cell membranes to the target tissues.
Mixtures
Both GB and VX are stored at several of the stockpile sites (LBAD, ANAD, PBA, TEAD, and UMDA). While munitions containing a given agent are placed in segregated bunkers, igloos, or storage buildings and, likewise, ton containers are segregated by agent type, the stockpile sites contain limited areas of contiguous rows of bunkers or other storage units containing unlike agents. While the probability of an accident such as an airplane crash into one of these areas of adjacent storage units resulting in release of more than one agent type is extremely low, such a release is considered here for the sake of completeness.
Thus, the question arises as to toxic effects of a GB-VX mixture if these agents were simultaneously released. In the only study found to date that addresses this issue, GB and VX were administered simultaneously and sequentially to mice (119) . When the agents were administered as a mixture of 0.5 LD50 of each agent (GB = 95 pg/kg, VX = 9 pg/kg9, the resulting mixture had an LD50 lower than one LD50 of either agent alone, meaning that the total effect was more than additive. When a 0.5 LD50 dose ofVX was administered 1 hr before a 0.5 LD50 dose of GB, brain and blood AChE were depressed less than by sequential administration of two 0.5 LD50 doses of GB given 1 hr apart. Thus, VX had a protective effect on blood and brain AChE depression produced by GB. However, when the nerve agents were administered in reverse order (0.5 LD50 of GB before 0.5 LD50 of VX), blood AChE inhibition was greater, but brain AChE inhibition was less than that induced by two serial 0. (14) . Tests of GA in antidote-protected chickens at 120 times the subcutaneous (SC) LD50 dose of 0.610 pmol/kg (14) [two 6 Little evidence for GB-induced neuropathy has accrued from studies in mammals. For example, agent GB failed to induce OPIDN in cats either at a supralethal dose, 1 mg/kg, SC, in atropinephysostigmine-protected animals (compared to the LD50 dose of 0.035 mg/kg, SC), or at multiple low-dose exposures adding up to the LD50 (147, 148) . The low doses (0.0035 mg/kg/day for 10 days or 0.007 mg/kg/day for 5 days, SC) generated no signs of cholinesterase poisoning. Agent GB (sarin I) also failed to induce OPIDN in CD rats exposed by gavage five times per week for 13 weeks (90 days) at doses ranging from 0 to 0.3 mg/kg/day (the MTD) (149) . A 15% decrease (p < 0.05) in NTE was seen only in the high-dose female group. Sarin II in similar experiments also failed to induce neuropathy in rats at doses up to the MTD, and no effects on NTE were seen at any dose (150) . It should be noted that the rat, unlike the cat, is relatively insensitive to full OPIDN induction (130, 132) and variably sensitive to histopathological damage. A study of the effects of high (convulsive, 5 pg/kg) or multiple small-dose GB exposures of rhesus monkeys on EEG patterns showed no difference in behavior between exposed and control animals examined both at 24 hr and 1 year after dosing (151) . No signs of atoxia were noted. Some primates are considered resistant to OPIDN induction, but others are susceptible (129) .
A recent report (152) of a small study in eight female Swiss albino mice suggests early changes characteristic of OPIDN induction resulting from low-dose GB exposure. The animals were exposed 20 min/day for 10 days, whole-body to 5 mg/m3 GB (17% of LC50, 600 mg/m /min, for this strain). This exposure regimen resulted in 27% inhibition of blood AChE and 19% inhibition of brain AChE but caused no signs of antiAChE toxicity. By day 14 In summary, while the possibility of a human developing OPIDN in response to a supralethal dose of GB cannot be ruled out, the major concern would be immediate treatment to prevent death. There is no evidence of GB causing OPIDN in humans, nor is there current evidence for this effect resulting from low-dose GB exposure (lower than those resulting in acute toxic effects) in any species other than the mouse.
Psychological effects. Acute exposure to GB has been shown to cause both transient and prolonged changes in psychological function. Evidence is available from several cases of accidental exposure in which the doses are unknown but effects can be categorized as severe or moderate (56, 156, 157) . At least some of the persistent changes may have resulted from brain damage caused by GB-induced convulsions (156) . Agent GB induction of transient depressive emotions, insomnia, excessive dreaming, and nightmares have been observed in volunteers in the absence of seizure activity (155) . Grob Sidell (71) considers that mild psychological changes resulting from nerve agent exposure to be more common than ordinarily recognized and to occur even in a small fraction of individuals experiencing few or no other signs of exposure; effects may persist from days to weeks. Sidell (71) also points out that the psychological effects can delay fitness for return to any work requiring full cognitive function and rapid decision-making.
That GB doses sufficient to cause acute toxic effects may also result in long-term psychological changes is further suggested by a recent study of workers previously acutely intoxicated by OP insecticides. This study documents persistent insecticide effects similar to those of nerve agent exposure on mental function and emotional state. Savage and colleagues (135) evaluated 100 individuals who had experienced 1 or more documented episodes of acute poisoning on average 9 years earlier (in at least 80% of the cases by parathion, methyl parathion, or malathion, dose unknown). These individuals showed mild but statistically significant deficits in intellectual ability, academic skills, abstract thinking ability, and speed and coordination on motor skill tests in comparison to matched controls. They evidenced more depression, irritability, confusion, and tendency to withdrawal than controls on an inventory by relatives and perceived themselves to have areas of difficulty with memory, thinking ability, and use of language.
Organophosphate insecticides are sequestered in body fat and gradually mobilized from these depots to a greater extent than the OP nerve agents as evidenced by their longer time course of recovery and need for repeated treatment with atropine (160, 161) . Thus, OP insecticides may be more likely than nerve agents to cause CNS effects and to induce changes persisting longer than those possibly induced by OP nerve agents.
EEG effects. Duffy and colleagues reported subtle long-term changes in human brain function after acute GB exposure (162, 163) . In these studies, exceedingly subtle changes in EEG patterns and increases in rapid eye movement (REM) sleep were observed at 1-6 years after accidental exposure to GB sufficient to cause acute signs and symptoms and to lower RBC-ChE by at least 25% below baseline. Statistically significant EEG changes were detected only by computer analysis in a group comparison of exposed workers with control subjects; trained neurologists were unable to distinguish by visual inspection between EEGs of exposed and unexposed individuals. Thus, the EEG changes are not considered clinically significant. Some of the workers studied by Duffy and colleagues (162, 163) had been studied earlier by Metcalf and Holmes (164) , who also reported on EEG, psychological, and neurological changes in persons exposed to OPs including insecticides and nerve agents. When the EEG patterns of the exposed OP worker group were compared with the EEGs of a control group of workers who had no exposure or access to OPs, minimal group differences were observed, consisting mainly of increased medium-voltage irregular 0 waves, usually during drowsiness [for details of EEG spectra differences, see Duffy et al. (162) ]. Note that, as in the study by Duffy and colleagues (162, 163) , these EEG changes were evident a year or more after exposure-during this time the workers had no other known OP exposure and showed no blood ChE activity depression. Comparing the "highly exposed" worker group to the "minimally exposed" worker group, Metcalf and Holmes (164) found memory, concentration, and sleep disturbances, as well as subtle EEG changes (not clinically significant) and minor motor coordination deficits. The Metcalf and Holmes report does not clarify whether the GB exposures of the subjects were recent, nor whether the persistent EEG changes could be correlated with the observed persistent psychological changes.
After the observation of EEG changes in GB-exposed workers, a study was carried out in monkeys in an attempt to substantiate these long-term EEG effects (151) . The monkeys were given either a single dose of GB (0.005 mg/kg, IV) that produced overt toxic signs or 10 smaller doses (0.001 mg/kg, IM, at weekly intervals) that resulted in no clinical signs. In both the acute and subchronic exposure groups, increases in jB activity were observed in the spontaneous cortical EEG patterns up to 1 year after exposure.
No difference in gross behavior was observed between treated and control animals. Another important finding from this study was that, at 1 year, there were greater differences in the EEG patterns of the animals that received the series of smaller doses (with no resulting clinical symptoms) than in the animals receiving the single dose.
Because the total dose in the series was twice that of the single dose, this suggests it is the total amount of GB received and not the induction of clinical effects that determined the degree of EEG alteration.
In summary, clinically insignificant EEG changes and increases in REM sleep were observed in the worker group exposed 1-6 years earlier to levels of GB sufficient to cause signs of toxicity. Changes were more evident in the worker group with more recent exposures or more than one episode of exposure (163) . Although some workers in the same population had experienced psychological changes, this study did not address any possible correlation between EEG changes and psychological effects. Thus, the meaning of subtle persistent EEG changes after GB exposure is unclear; there may be no meaningful behavioral or physiological correlates. Levels of GB exposure too low to cause acute toxic signs and symptons have not been tested for the ability to induce persistent EEG changes.
Cardiac effects. Another potential delayed effect of GB exposure is cardiac damage. In a study of OP insecticide poisonings, certain clinical effects such as cardiac problems often showed a delay in their onset (160) . Agent GB has been shown to cause cardiomyopathy in rats in doses sufficient to cause convulsions in many of the animals (0.111-0.17 mg/kg, SC) (65) . Cardiac lesions were seen only in animals that had convulsed with resulting brain lesions. The cardiomyopathy may result from CNS damage and consequent sympathetic overstimulation. Agent VX OPIDN. Agent VX shows no potential for inducing OPIDN (Table 5 ). In tests of the ability of nerve agents to inhibit NTE in vitro, VX was at least 1000-fold less active than agent GB (14, 136) . Three VX-related thiolates were also ineffective at in vitro inhibition of NTE (14) . Single IM or SC injections of VX at 0.15 mg/kg (5 times the LD50, IM) in atropine-protected chickens produced neither inhibition of NTE nor histological or behavioral evidence of OPIDN (165) . A structurally unrelated fluoridothionate compound was neuropathic in an acute test in the chicken at 5 mg/kg, IM (142) . The ability of VX to induce OPIDN has also been tested in antidote-protected chickens when injected IM at 0.04 mg/kg for 90-100 days. The results of this subchronic exposure test were negative; no behavioral signs or histological degeneration of spinal cord or muscles were produced, in contrast to effects seen in the positive controls exposed to diisopropylfluorophosphonate (DFP) (166) . In summary, there is no indication that VX has any potential at low or high doses for the induction of OPIDN in human beings or other species either with ---im.-eM- Table 5 . (140, 141) .
Genotoxicity. In tests of mutagenicity, GA was weakly mutagenic in the mouse lymphoma assay and in the Ames test using S. typhimurium (170) . Agent GA induced sister chromatid exchanges (SCE) in vitro in mouse cells but not in vivo in mice (170) . Agent Negative results in genotoxicity studies of GB as summarized in Table 6 support the likelihood that GB is not carcinogenic. Agent GB did not induce mutations in the Ames test (171) nor in mouse lymphoma cells (171) ; it failed to induce SCE (174) Environmental Health Perspectives Teratogenicity and reproductive toxicity.
Tests for teratogenic effects of GB in the rabbit and rat were negative (176) ( Denk (179) [as reviewed by Weimer et al. (169) ] reported that no dominant lethal mutations or adverse effects on reproductive performance occurred in rats through three generations after exposure for 10 months to airborne GB at concentrations of 0.001 or 0.0001 mg/mi3 (see Table 6 ). These levels were so low that no overt signs of toxicity were produced. Another study evaluated testicular atrophy in Fischer rats after a 6-month exposure via SC or intraperitoneal injections of low doses of GB; no differences were found between treated and nontreated animals (181). Weimer et al. (169) reported no reproductive effects of longterm GB inhalation on any group of mice or rats except for the Fischer rats, which exhibited an increased incidence of testicular atrophy, a condition to which this strain is genetically susceptible. Table 6 ). These studies include mutagenicity in bacteria (S. typhimurium, Ames assay), yeast (Saccharomyces cerevisiae), fruitflies (Drosophila melanogaster), and in a mammalian cell line (mouse lymphoma L5178Y). In the bacteria and yeast studies, VX (172) . Results were negative in both the Ames assay (172, 173) and the S. cerevisiae assays (173) . In the Drosophila sex-linked, recessive lethal mutation test, only one mutation was observed at the higher VX concentration (0.004 mg/mr3), for a mutation percentage of 0.5% (172) . A repeat test at the same concentration yielded no mutations. Thus, results were also negative for VX in this mutagenicity assay.
The fourth assay for mutagenic activity involved the use of mouse lymphoma cells, which may provide better health risk estimates for humans than tests using bacteria or yeast. Again, in this assay, VX was tested with and without metabolic activation. At lower concentrations (0.001-0.02 mg/ml), there was no statistically significant increase in the mutation frequency; at the higher test concentrations (0.02-0.1 mg/ml), there was a small but statistically significant increase in the number of mutants that appeared to be related to dose but not to activation (173) . Compared with controls, this increase in mutations was less than the twofold increase set as a criterion for a positive mutagen (182, 183) ; thus VX was considered by the authors to be a nonmutagen. Agent VX also gave negative results in the SCE assay, which tests for chromosomal damage rather than mutations.
Teratogenicity. Data on the potential of VX to affect fetal development (teratogenesis) come from the accidental exposure of sheep to lethal concentrations of VX and from controlled studies in rats and rabbits (see Table 6 ). Van The teratogenic potential of VX in rats and rabbits was tested by SC injection of 0.00025 to 0.004 mg/kg/day on gestational days 6 through 15 in rats and days 6 through 19 in rabbits. The pregnant animals were killed on day 20; the fetuses were removed and examined for body weight and for skeletal and organ abnormalities. Results of the studies in rats showed no statistically significant relationship between the dose of VX and any of the parameters studied (173) . Results of the teratogenic studies in rabbits were also negative. * -lsa 0* 9SZ -oAN~u * =as1] | I S is ; lo . .
A preliminary study (177) suggested embryotoxicity of VX to rat fetuses after 0.03 mg SC doses to the mother and embryolethality to chick embryos at 0.032 mg/egg. Another preliminary study (178) suggested that VX may exert behavioral toxicity effects on the rat fetus after repeated SC doses of 0.005 mg/kg at varying times during fetal development. These results indicate that further study may be warranted.
Reproductive toxicity. Information to date suggests that neither acute nor chronic VX exposure has deleterious effects on reproductive potential. One data set comes from the 1968 Skull Valley incident of acute accidental exposure of sheep to unknown levels of VX (111). The exposed ewes were evaluated for their reproductive capacity by breeding them 5-6 months after exposure. Although the dose of VX received by the ewes is unknown, it was sufficient to cause signs of acute-toxicity. No effects on reproductive capacity were found in these animals. The results of a three-generation assay for reproductive potential were reported to be negative in Sprague-Dawley rats (171 ) ( 
Implications for Public Protection
Several aspects of nerve agent physicochemical characteristics and toxicity have ramifications of particular importance in planning for public protection during continued storage and the active phase of the Chemical Stockpile Disposal Program. In view of its volatility, GB mainly constitutes an inhalation hazard. It would be expected to disperse more widely than the more dense and less volatile VX. However, all nerve agents are readily adsorbed into porous media such as wood, masonry, plastic, painted surfaces, and fabrics, from which they may outgas over varying periods of time (98) . Thus, all nerve agents, but especially VX, may persist in common building materials and on agricultural crops, posing dermal and inhalation exposure hazards (18) . Nondestructive decontamination methods are currently unavailable for porous surfaces and materials (184) .
Agent control limits that are protective in terms of chronic inhalation exposure of both public and occupational populations are presented in Table 7 (185) . Work is underway to develop equivalent control limits for drinking water and food items; currently, no such limits exist for porous surfaces (186) . Existing technology is adequate to monitor low air concentrations to ensure compliance with atmospheric control limits, but further development is needed to detect comparably low levels in water and foodstuffs.
Even mild to moderate nerve agent exposures may produce mental and emotional effects that, together with effects such as nausea, may have a pronounced impact on public response to emergency warnings. The implications for an exposed civilian population include possible confusion, inability to follow directions provided in conjunction with public warnings from emergency personnel, inability or enhanced unwillingness to cooperate with authorities in the event of an evacuation notice (e.g., inability to drive), and limited ability to cooperate during decontamination and treatment procedures. Thus, early warning systems are of singular importance, as well as prior education of the public in adequate response measures.
Likewise, even mild or moderate exposures to emergency responders may render them mentally unable to return to duty for an extended time after decontamination and treatment result in the cessation of physical symptoms (29, 71) . In any case, responders should not return to any duty for which there is potential for reexposure to an anti-ChE agent before RBC-ChE activity returns to 80% or more of individual baseline nor before having been asymptomatic for at least 7 days (18/). Thus, self-contamination in the course of emergency response activities such as casualty decontamination and treatment must be stringently avoided.
Conclusions
The overreaching concern with regard to nerve agent exposure is the extraordinarily high acute toxicity of these substances. These agents were designed to produce rapid incapacitation or death at exceedingly low doses. Inability to perform complex tasks or tasks requiring good vision (especially night vision) can result from low to moderate nerve agent doses. Such incapacitation may be a consequence of psychological effects alone or in combination with gastrointestinal, ocular, or respiratory effects and could have a significant negative impact on a population's ability to respond to emergency warnings and instructions.
The congressional mandate to destroy U. S. stockpiles of unitary chemical warfare agents by the end of this decade was the stimulus for gathering and analyzing the widely scattered literature on the toxicity of the stockpiled warfare agents as summarized here and, to some extent, in other reviews. The U. S. Army Chemical Stockpile Disposal Program (CSDP) is currently designed to carry out on-site, high-temperature incineration of organophosphate nerve agents stored in bulk or incorporated into munitions. The potential for an inadvertent release with off-site consequences is considered exceedingly small (probabilities of 10-4 to 10-10for individual incidents) during continued storage or on-site stockpile destruction. The continued storage option is estimated to entail greater risks of fatalities than on-site disposal. The potential for low-probability but high-consequence releases has raised public concern in the vicinity of the stockpile sites and is resulting in an extensive upgrading of emergency preparedness in the civilian sector in advance of the CSDP. This analysis was prepared to assist the medical and emergency planning communities and to address various issues emerging as concerns in the course of public participation in the planning process.
The nerve agents of primary concern in the unitary stockpile are GB (sarin) and VX; GA (tabun) is present in a small quantity at only one location in the United States (Tooele Army Depot in Utah). Other states hosting or immediately adjacent to sites where nerve agents are stored include Alabama, Arkansas, Illinois, Indiana, Kentucky, Oregon, and Washington.
Marked differences in the volatility of the nerve agents result in significant differences in the potential geographic area affected by an inadvertent release, in persistence in the environment, and in the likely route of human exposure. Agent VX, being less volatile than GA and GB, would be expected to disperse less widely but to be more persistent and to present more of a contact hazard and potential ingestion hazard from contaminated agricultural products. Degassing of VX from porous surfaces (e.g., building materials) may pose problems of detection and decontamination before reentry can be determined to be safe. Agents GA and GB are primarily inhalation hazards, tend to disperse rapidly, and present little contact or ingestion hazard.
Agents GB and VX are both present at five sites ( Table  2 are based partially on animal data from rodent species that have protective enzymes such as carboxylesterase which humans lack. Thus, the estimates must be viewed with caution as humans may be more sensitive than some of the species on which LD values and other toxicity indices are based. Where human data were used in combination with animal data, they were based on experiments with young, healthy, adult male military volunteers. These volunteers are clearly not representative of the general population. Special populations, such as infants, may be more sensitive.
Tests of agent VX summarized in Table 5 demonstrate no potential to induce delayed neuropathy in any species. Agents GA and, to a somewhat greater extent, GB, have limited potential to induce OPIDN, based on studies in antidote-protected chickens exposed to supralethal doses. From these studies, it appears that OPIDN induction would be possible only at GA or GB doses that would be lethal to unprotected humans. One as-yet unverified small low-dose inhalation study in 
